In-house roundup: How to manage AI applications; pharma unconcerned by NHS provision; fintech embraces open source

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

In-house roundup: How to manage AI applications; pharma unconcerned by NHS provision; fintech embraces open source

Drugs

Managing IP rounds up the latest news and analysis from patent-focused businesses



Drugs

How financial services firms manage AI applications

Counsel at Equifax, Morgan Stanley and American Express say streamlining relationships with external counsel and disclosing data sets correctly are key to prosecuting artificial intelligence patents. Read more... 

Pharma companies unconcerned by NHS notification in preliminary injunctions

In-house sources say changes to the England and Wales Patents Court Guide setting out that health authorities must be notified in the case of an injunction for an approved therapeutic product are not a cause for concern. Read more... 

Digital transformation pushes firms to embrace open source

Microsoft, JPMorgan and Wells Fargo explain how the cloud, AI and data sets technologies are driving them to open source and how that change is affecting patent strategies. Read more... 





more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
Schwitulla is the head of litigation management at Nokia in Germany
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article